Scienture Holdings, Inc. (Nasdaq: SCNX) announced a securities purchase agreement with institutional investors for 3,225,000 shares of common stock at an offering price of $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share with expected proceeds of $3.9 million.
Placement Agent
Maxim Group LLC is acting as the sole placement agent for the offering.
Registration Statement
The offering is made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198) filed with the SEC.
- The registered direct offering will provide Scienture Holdings, Inc. with additional capital for its pharmaceutical operations and product development.
- Securing funds through institutional investors enhances the financial position and potential growth opportunities for the company.
The successful completion of the registered direct offering demonstrates investor confidence in Scienture Holdings, Inc.'s business strategy and future prospects in the pharmaceutical industry.